Harnessing Medicinal Chemical Intuition from Collective Intelligence.

Journal: Journal of medicinal chemistry
Published Date:

Abstract

Over the past decade, collective intelligence, i.e., the intelligence that emerges from collective efforts, has transformed complex problem-solving and decision-making. In drug discovery, decision-making often relies on medicinal chemistry intuition. The present study explores the application of collective intelligence in drug discovery, focusing on lead optimization. Ninety-two Sanofi researchers with diverse expertise participated anonymously in an exercise centered on ADMET-related questions. Their feedback was used to build a collective intelligence agent, which was compared to an artificial intelligence model. The study led to three major conclusions: first, collective intelligence improves decision-making in optimizing ADMET endpoints, compared to individual decisions. Second, collective intelligence outperforms artificial intelligence for all other endpoints but hERG inhibition. Finally, we observe complementarity between collective human and artificial intelligence. Overall, this research highlights the potential of collective intelligence in drug discovery and the importance of a synergistic approach combining human and artificial intelligence in project decision making.

Authors

  • Pierre Llompart
    Molecular Design Sciences, Integrated Drug Discovery, Sanofi, 1 Imp. Des Ateliers, Vitry-sur-Seine 94400, France.
  • Kwame Amaning
    Molecular Design Sciences, Integrated Drug Discovery, Sanofi, 1 Imp. Des Ateliers, Vitry-sur-Seine 94400, France.
  • Marc Bianciotto
    Molecular Design Sciences - Integrated Drug Discovery, Sanofi R&D, 94400 Vitry-sur-Seine, France.
  • Bruno Filoche-Rommé
    Molecular Design Sciences, Integrated Drug Discovery, Sanofi, 1 Imp. Des Ateliers, Vitry-sur-Seine 94400, France.
  • Yann Foricher
    Small Molecules Medicinal Chemistry, Integrated Drug Discovery, Sanofi, 1 Imp. Des Ateliers, Vitry-sur-Seine 94400, France.
  • Pablo Mas
    Molecular Design Sciences, Integrated Drug Discovery, Sanofi, 1 Imp. Des Ateliers, Vitry-sur-Seine 94400, France.
  • David Papin
    Molecular Design Sciences, Integrated Drug Discovery, Sanofi, 1 Imp. Des Ateliers, Vitry-sur-Seine 94400, France.
  • Jean-Philippe Rameau
    Molecular Design Sciences, Integrated Drug Discovery, Sanofi, 1 Imp. Des Ateliers, Vitry-sur-Seine 94400, France.
  • Laurent Schio
    Integrated Drug Discovery, Sanofi, 1 Imp. Des Ateliers, Vitry-sur-Seine 94400, France.
  • Gilles Marcou
    Laboratoire de Chemoinformatique, UMR 7140, Université de Strasbourg , 1 rue Blaise Pascal, Strasbourg 67000, France.
  • Alexandre Varnek
    Laboratoire de Chemoinformatique, UMR 7140, Université de Strasbourg , 1 rue Blaise Pascal, Strasbourg 67000, France.
  • Mehdi Moussaid
    Center for Adaptive Rationality, Max Planck Institute for Human Development, Berlin 14195, Germany.
  • Claire Minoletti
    Molecular Design Sciences, Integrated Drug Discovery, Sanofi, 1 Imp. Des Ateliers, Vitry-sur-Seine 94400, France.
  • Paraskevi Gkeka
    Integrated Drug Discovery, Sanofi R&D, 91385 Chilly-Mazarin, France.